Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
In the featured video, renowned expert Hagop Kantarjian, MD, a professor at MD Anderson Cancer Center, delves into groundbreaking developments in the treatment of adult acute lymphoblastic leukemia (ALL). With a focus on cutting-edge strategies, including third-generation TKIs like Ponatinib and Blinatumomab, as well as CD19/CD22-targeting antibodies, Hagop Kantarjian, MD underscores their promising potential to elevate cure rates while diminishing the demand for intensive chemotherapy.
These remarkable breakthroughs have translated into remarkable estimated four-year survival rates, exceeding eighty percent for specific cases. Hagop Kantarjian, MD applauds the conference’s exceptional speakers, brilliant discourse, and expert perspectives, making the event both an enjoyable and enlightening experience.